Portal Hypertension - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 51 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Portal Hypertension - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Portal Hypertension - Pipeline Review, H2 2014', provides an overview of the Portal Hypertension's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Portal Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Portal Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Portal Hypertension
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Portal Hypertension and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Portal Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Portal Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Portal Hypertension
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Portal Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Portal Hypertension Overview 6
Therapeutics Development 7
Pipeline Products for Portal Hypertension - Overview 7
Pipeline Products for Portal Hypertension - Comparative Analysis 8
Portal Hypertension - Therapeutics under Development by Companies 9
Portal Hypertension - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Portal Hypertension - Products under Development by Companies 12
Portal Hypertension - Companies Involved in Therapeutics Development 13
Conatus Pharmaceuticals Inc. 13
Intercept Pharmaceuticals, Inc. 14
Mezzion Pharma Co. Ltd. 15
Ono Pharmaceutical Co., Ltd. 16
Phenex Pharmaceuticals AG 17
Portal Hypertension - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 24
Drug Profiles 25
emricasan - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
obeticholic acid - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ONO-1266 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PX-20606 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
udenafil - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Portal Hypertension - Recent Pipeline Updates 35
Portal Hypertension - Dormant Projects 43
Portal Hypertension - Discontinued Products 44
Portal Hypertension - Product Development Milestones 45
Featured News & Press Releases 45
Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting 45
Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting 46
Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension 47
Nov 08, 2012: Intercept Pharma To Present Phase IIa Portal Hypertension Data At AASLD's Annual Liver Meeting 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables
Number of Products under Development for Portal Hypertension, H2 2014 7
Number of Products under Development for Portal Hypertension - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Portal Hypertension - Pipeline by Conatus Pharmaceuticals Inc., H2 2014 13
Portal Hypertension - Pipeline by Intercept Pharmaceuticals, Inc., H2 2014 14
Portal Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2014 15
Portal Hypertension - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 16
Portal Hypertension - Pipeline by Phenex Pharmaceuticals AG, H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 24
Portal Hypertension Therapeutics - Recent Pipeline Updates, H2 2014 35
Portal Hypertension - Dormant Projects, H2 2014 43
Portal Hypertension - Discontinued Products, H2 2014 44